推薦產品
生物源
mouse
品質等級
抗體表格
purified antibody
抗體產品種類
primary antibodies
無性繁殖
RAS 10, monoclonal
形狀
liquid
包含
≤0.1% sodium azide as preservative
物種活性
human, mouse, rat
製造商／商標名
Calbiochem®
儲存條件
do not freeze
同型
IgG2a
運輸包裝
wet ice
儲存溫度
2-8°C
目標翻譯後修改
unmodified
基因資訊
human ... KRAS(3845)
一般說明
可识别SW480和Y1细胞以及乳腺癌组织中的~21 kDa H-、K-和N-Ras蛋白。
该抗Pan-Ras（Ab-3）小鼠mAb（RAS 10）经验证可用于FC、冰冻切片、免疫印迹、IF、IP和石蜡切片，以检测Pan-Ras（Ab-3）。
通过用指定的免疫原免疫BALB/c小鼠并将脾细胞与SP2/0骨髓瘤细胞融合而产生的纯化小鼠单克隆抗体（请参阅应用参考）。可识别~21 kDa Ras蛋白。
免疫原
重组人p21 Ras
應用
流式细胞术分析（2.5 g/ml）
冷冻切片（2.5 g/ml）
免疫印迹（0.1-3 g/ml，化学发光和比色法，请参阅应用参考文献）
免疫荧光（2.5 g/ml，请参阅应用参考文献）
免疫沉淀（1 g/样品）
石蜡切片（2.5 g/ml，需要皂苷预处理）
包裝
请参考特定浓度批号的标签。
警告
毒性：标准处理（A）
分析報告
阳性对照
SW480或Y1细胞或乳腺癌组织
SW480或Y1细胞或乳腺癌组织
其他說明
Rodenhuis, S. et al., 1992.Cancer Res. (Suppl)52, 2665s.
Sidransky, D., et al. 1992.Science256, 102.
Hamer, P.J., et al. 1990.Hybridoma9, 573.
Bos, J.L.1989.Cancer Res.49, 4682.
Furth, M. E., et al. 1987.Oncogene1, 47.
Kraus, M.H., et al. 1984.Proc.Natl.Acad.Sci. USA81, 5384.
Shimizu, K., et al. 1983.Proc.Natl.Acad.Sci. USA80, 2112.
Taparowsky, E., et al. 1983.Cell34, 581.
Ellis, R.W., et al. 1981.Nature292, 506.
Shih, T.Y., et al. 1980.Nature287, 686.
Sidransky, D., et al. 1992.Science256, 102.
Hamer, P.J., et al. 1990.Hybridoma9, 573.
Bos, J.L.1989.Cancer Res.49, 4682.
Furth, M. E., et al. 1987.Oncogene1, 47.
Kraus, M.H., et al. 1984.Proc.Natl.Acad.Sci. USA81, 5384.
Shimizu, K., et al. 1983.Proc.Natl.Acad.Sci. USA80, 2112.
Taparowsky, E., et al. 1983.Cell34, 581.
Ellis, R.W., et al. 1981.Nature292, 506.
Shih, T.Y., et al. 1980.Nature287, 686.
p21ras的表达水平在不同组织中是可变的。因此，我们建议在免疫印迹分析之前进行浓缩步骤，以获得最佳结果。在单个系统中，应对抗体进行滴定以获得最佳结果。
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our 產品選擇工具.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 1
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Lauren L Fonseca et al.
Translational oncology, 14(1), 100880-100880 (2020-10-20)
Ras mutations are present in only a subset of sporadic human cutaneous squamous cell carcinomas (cSCC) even though Ras is activated in most. This suggests that other mechanisms of Ras activation play a role in the disease. The aberrant expression
J M English et al.
The Journal of biological chemistry, 274(44), 31588-31592 (1999-10-26)
The activity of the catalytic domain of the orphan MAP kinase ERK5 is increased by Ras but not Raf-1 in cells, which suggests that ERK5 might mediate Raf-independent signaling by Ras. We found that Raf-1 does contribute to Ras activation
Christian H Klein et al.
International journal of cancer, 144(4), 767-776 (2018-09-09)
Ras proteins, most notably KRas, are prevalent oncogenes in human cancer. Plasma membrane localization and thereby signaling of KRas is regulated by the prenyl-binding protein PDEδ. Recently, we have reported the specific anti-proliferative effects of PDEδ inhibition in KRas-dependent human
Qing-Fen Li et al.
Cell reports, 24(11), 2869-2882 (2018-09-13)
Cerebrovascular malformations (CVMs) affect approximately 3% of the population, risking hemorrhagic stroke, seizures, and neurological deficits. Recently Ras mutations have been identified in a majority of brain arterio-venous malformations. We generated an endothelial-specific, inducible HRASV12 mouse model, which results in
A Pelosi et al.
Oncogene, 32(31), 3648-3654 (2012-09-12)
MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, are involved in many complex cellular processes. Several miRNAs are differentially expressed in hematopoietic tissues and play important roles in normal differentiation, but, when aberrantly regulated, contribute to the abnormal
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務